News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Santarus Inc. (SNTS) Announces Presentation of SAN-300 Phase I Data at 2013 American College of Rheumatology Annual Meeting



10/25/2013 7:18:49 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Santarus, Inc. (NASDAQ:SNTS) today announced that data from its Phase I clinical study with its investigational drug SAN-300, a novel antibody that inhibits very late antigen-1 (VLA-1; a1ß1 integrin), will be featured in a poster presentation at the 2013 American College of Rheumatology.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES